| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 39 | 2025 | 1053 | 7.590 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 13 | 2024 | 50 | 5.430 |
Why?
|
| Genetic Testing | 17 | 2025 | 565 | 5.130 |
Why?
|
| Colon | 9 | 2025 | 540 | 3.040 |
Why?
|
| Celiac Disease | 13 | 2019 | 219 | 2.380 |
Why?
|
| Carcinoma, Pancreatic Ductal | 5 | 2024 | 131 | 2.350 |
Why?
|
| Stomach Neoplasms | 10 | 2025 | 308 | 2.220 |
Why?
|
| Adenomatous Polyposis Coli | 8 | 2025 | 44 | 2.180 |
Why?
|
| Early Detection of Cancer | 13 | 2025 | 482 | 2.050 |
Why?
|
| Calcitriol | 4 | 2021 | 173 | 2.010 |
Why?
|
| Organoids | 6 | 2025 | 76 | 2.010 |
Why?
|
| Genetic Predisposition to Disease | 25 | 2025 | 2465 | 1.960 |
Why?
|
| Pancreatic Neoplasms | 7 | 2024 | 715 | 1.950 |
Why?
|
| Neoplastic Syndromes, Hereditary | 7 | 2025 | 29 | 1.880 |
Why?
|
| Germ-Line Mutation | 9 | 2025 | 381 | 1.720 |
Why?
|
| Gastroenterology | 6 | 2025 | 157 | 1.650 |
Why?
|
| Aspirin | 2 | 2025 | 167 | 1.500 |
Why?
|
| Colonoscopy | 12 | 2023 | 303 | 1.450 |
Why?
|
| Epigenomics | 2 | 2023 | 109 | 1.360 |
Why?
|
| Genetic Counseling | 4 | 2022 | 101 | 1.280 |
Why?
|
| Humans | 108 | 2025 | 93515 | 1.260 |
Why?
|
| Vitamin D | 7 | 2017 | 272 | 1.230 |
Why?
|
| DNA Mismatch Repair | 6 | 2024 | 58 | 1.090 |
Why?
|
| MutL Protein Homolog 1 | 5 | 2024 | 35 | 1.080 |
Why?
|
| Uridine Phosphorylase | 2 | 2018 | 4 | 1.080 |
Why?
|
| Middle Aged | 47 | 2025 | 27573 | 1.070 |
Why?
|
| Glutens | 6 | 2019 | 85 | 1.050 |
Why?
|
| Heterozygote | 7 | 2024 | 382 | 1.000 |
Why?
|
| Aged | 33 | 2025 | 20434 | 0.950 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2017 | 2484 | 0.940 |
Why?
|
| Male | 50 | 2025 | 44557 | 0.940 |
Why?
|
| Patient Compliance | 2 | 2018 | 237 | 0.880 |
Why?
|
| Female | 53 | 2025 | 48702 | 0.880 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2025 | 110 | 0.880 |
Why?
|
| Colonic Polyps | 3 | 2022 | 137 | 0.860 |
Why?
|
| Risk Factors | 19 | 2025 | 5899 | 0.820 |
Why?
|
| Retrospective Studies | 18 | 2025 | 10164 | 0.730 |
Why?
|
| Patient Advocacy | 1 | 2023 | 63 | 0.730 |
Why?
|
| Adenoma | 3 | 2022 | 258 | 0.730 |
Why?
|
| HLA-DQ Antigens | 3 | 2019 | 51 | 0.720 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2022 | 9 | 0.720 |
Why?
|
| Glucocorticoids | 2 | 2014 | 362 | 0.700 |
Why?
|
| Antigens, CD | 5 | 2025 | 476 | 0.690 |
Why?
|
| Fellowships and Scholarships | 1 | 2023 | 145 | 0.680 |
Why?
|
| Transcription, Genetic | 3 | 2017 | 1117 | 0.680 |
Why?
|
| Mutation | 4 | 2025 | 4272 | 0.680 |
Why?
|
| Health Policy | 2 | 2021 | 206 | 0.650 |
Why?
|
| Intestine, Small | 3 | 2024 | 310 | 0.650 |
Why?
|
| Microsatellite Instability | 6 | 2025 | 64 | 0.650 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2017 | 646 | 0.640 |
Why?
|
| Diet, Gluten-Free | 3 | 2019 | 60 | 0.630 |
Why?
|
| Food Handling | 1 | 2019 | 7 | 0.620 |
Why?
|
| Genomics | 3 | 2025 | 848 | 0.610 |
Why?
|
| Health Status Disparities | 3 | 2021 | 219 | 0.600 |
Why?
|
| Cadherins | 6 | 2025 | 180 | 0.600 |
Why?
|
| Quantitative Trait Loci | 3 | 2025 | 630 | 0.590 |
Why?
|
| Legislation, Medical | 1 | 2019 | 9 | 0.590 |
Why?
|
| Adult | 32 | 2025 | 27918 | 0.580 |
Why?
|
| Predictive Value of Tests | 8 | 2025 | 1713 | 0.580 |
Why?
|
| BRCA2 Protein | 1 | 2020 | 173 | 0.580 |
Why?
|
| Genetic Variation | 4 | 2020 | 1415 | 0.570 |
Why?
|
| BRCA1 Protein | 1 | 2020 | 214 | 0.570 |
Why?
|
| Biomarkers, Tumor | 7 | 2024 | 1660 | 0.560 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2019 | 160 | 0.560 |
Why?
|
| Uridine | 1 | 2018 | 54 | 0.560 |
Why?
|
| Intestinal Diseases | 1 | 2019 | 84 | 0.550 |
Why?
|
| Gene Expression Regulation | 3 | 2017 | 1985 | 0.540 |
Why?
|
| Colonic Diseases | 1 | 2018 | 59 | 0.540 |
Why?
|
| Cell Proliferation | 2 | 2014 | 1741 | 0.540 |
Why?
|
| Receptors, Calcitriol | 3 | 2018 | 131 | 0.540 |
Why?
|
| Medicare | 1 | 2021 | 455 | 0.530 |
Why?
|
| Postoperative Period | 1 | 2018 | 315 | 0.530 |
Why?
|
| Hematoma | 1 | 2018 | 106 | 0.530 |
Why?
|
| Blood Coagulation Disorders | 1 | 2018 | 66 | 0.520 |
Why?
|
| United States | 16 | 2023 | 7622 | 0.520 |
Why?
|
| Endometrial Neoplasms | 3 | 2024 | 227 | 0.520 |
Why?
|
| Biopsy | 8 | 2021 | 1175 | 0.520 |
Why?
|
| Transcriptome | 2 | 2021 | 762 | 0.520 |
Why?
|
| Jejunal Neoplasms | 1 | 2017 | 9 | 0.510 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2017 | 11 | 0.510 |
Why?
|
| Epithelial Cells | 2 | 2018 | 700 | 0.500 |
Why?
|
| Patient Selection | 3 | 2019 | 690 | 0.500 |
Why?
|
| Referral and Consultation | 2 | 2025 | 375 | 0.490 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 1053 | 0.490 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 242 | 0.490 |
Why?
|
| DNA Damage | 1 | 2018 | 389 | 0.480 |
Why?
|
| Breast Neoplasms | 4 | 2024 | 3110 | 0.470 |
Why?
|
| Mass Screening | 2 | 2023 | 696 | 0.460 |
Why?
|
| Attitude | 1 | 2016 | 132 | 0.460 |
Why?
|
| Carcinoma, Signet Ring Cell | 2 | 2025 | 10 | 0.450 |
Why?
|
| Precision Medicine | 1 | 2019 | 456 | 0.440 |
Why?
|
| Young Adult | 11 | 2025 | 6930 | 0.420 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2014 | 16 | 0.420 |
Why?
|
| Family | 1 | 2015 | 324 | 0.400 |
Why?
|
| Risk Assessment | 8 | 2025 | 2441 | 0.400 |
Why?
|
| Genome-Wide Association Study | 6 | 2017 | 1762 | 0.390 |
Why?
|
| Adenocarcinoma | 4 | 2024 | 1173 | 0.380 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2012 | 83 | 0.380 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 208 | 0.370 |
Why?
|
| DNA, Neoplasm | 2 | 2010 | 266 | 0.370 |
Why?
|
| Physicians | 2 | 2019 | 682 | 0.370 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 813 | 0.370 |
Why?
|
| Diet | 5 | 2021 | 460 | 0.370 |
Why?
|
| Polymorphism, Genetic | 2 | 2018 | 826 | 0.360 |
Why?
|
| Time Factors | 8 | 2021 | 5410 | 0.340 |
Why?
|
| Aged, 80 and over | 9 | 2024 | 7061 | 0.340 |
Why?
|
| Incidence | 5 | 2021 | 1701 | 0.310 |
Why?
|
| Cross-Sectional Studies | 4 | 2025 | 1847 | 0.300 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 589 | 0.290 |
Why?
|
| Adaptive Immunity | 3 | 2015 | 179 | 0.290 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 3 | 2019 | 25 | 0.290 |
Why?
|
| Chromatin | 2 | 2023 | 440 | 0.290 |
Why?
|
| Case-Control Studies | 9 | 2024 | 1931 | 0.280 |
Why?
|
| Vitamin D3 24-Hydroxylase | 2 | 2021 | 6 | 0.280 |
Why?
|
| Colitis, Ulcerative | 2 | 2014 | 800 | 0.270 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2007 | 13 | 0.270 |
Why?
|
| Quality of Life | 1 | 2016 | 1780 | 0.270 |
Why?
|
| Mastocytosis | 1 | 2007 | 14 | 0.270 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 1275 | 0.270 |
Why?
|
| Crohn Disease | 1 | 2014 | 808 | 0.260 |
Why?
|
| Vitamins | 2 | 2021 | 85 | 0.260 |
Why?
|
| DNA-Binding Proteins | 6 | 2022 | 1234 | 0.250 |
Why?
|
| Tissue Culture Techniques | 2 | 2018 | 81 | 0.240 |
Why?
|
| DNA Mutational Analysis | 3 | 2021 | 543 | 0.230 |
Why?
|
| Adolescent | 7 | 2024 | 9606 | 0.230 |
Why?
|
| Intestinal Mucosa | 4 | 2019 | 824 | 0.230 |
Why?
|
| Gastroscopy | 1 | 2025 | 25 | 0.230 |
Why?
|
| Intestinal Polyposis | 1 | 2025 | 5 | 0.230 |
Why?
|
| Cdh1 Proteins | 1 | 2025 | 2 | 0.230 |
Why?
|
| Duodenal Neoplasms | 1 | 2025 | 21 | 0.230 |
Why?
|
| Colonic Neoplasms | 4 | 2020 | 579 | 0.230 |
Why?
|
| Decision Trees | 1 | 2025 | 64 | 0.220 |
Why?
|
| DNA Methylation | 4 | 2020 | 697 | 0.220 |
Why?
|
| Anticipation, Genetic | 1 | 2024 | 2 | 0.220 |
Why?
|
| Inflammation | 4 | 2020 | 1050 | 0.220 |
Why?
|
| Prospective Studies | 5 | 2025 | 4560 | 0.220 |
Why?
|
| Pathologists | 1 | 2025 | 40 | 0.220 |
Why?
|
| Interleukin-15 | 3 | 2015 | 75 | 0.220 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2025 | 537 | 0.210 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2015 | 304 | 0.210 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2015 | 319 | 0.210 |
Why?
|
| Biomarkers | 3 | 2019 | 1910 | 0.200 |
Why?
|
| Phenotype | 3 | 2020 | 2544 | 0.200 |
Why?
|
| Adenomatous Polyps | 2 | 2025 | 15 | 0.190 |
Why?
|
| Social Welfare | 1 | 2023 | 20 | 0.190 |
Why?
|
| Perception | 1 | 2024 | 179 | 0.190 |
Why?
|
| Age Factors | 3 | 2020 | 1906 | 0.190 |
Why?
|
| Rectal Neoplasms | 1 | 2023 | 132 | 0.190 |
Why?
|
| Age of Onset | 2 | 2021 | 342 | 0.180 |
Why?
|
| Alleles | 2 | 2017 | 1139 | 0.180 |
Why?
|
| Proportional Hazards Models | 1 | 2024 | 889 | 0.180 |
Why?
|
| Chicago | 3 | 2014 | 1464 | 0.180 |
Why?
|
| ErbB Receptors | 2 | 2018 | 506 | 0.180 |
Why?
|
| Intestinal Polyps | 1 | 2022 | 27 | 0.180 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2014 | 192 | 0.180 |
Why?
|
| Counselors | 1 | 2022 | 7 | 0.180 |
Why?
|
| MicroRNAs | 2 | 2020 | 580 | 0.180 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 2802 | 0.180 |
Why?
|
| Point-of-Care Systems | 1 | 2023 | 150 | 0.180 |
Why?
|
| Text Messaging | 1 | 2022 | 35 | 0.180 |
Why?
|
| Mucous Membrane | 1 | 2022 | 82 | 0.170 |
Why?
|
| MutS Homolog 2 Protein | 3 | 2019 | 33 | 0.170 |
Why?
|
| Gene Frequency | 3 | 2014 | 700 | 0.170 |
Why?
|
| Southeastern United States | 1 | 2021 | 9 | 0.170 |
Why?
|
| Sex Factors | 2 | 2015 | 1105 | 0.170 |
Why?
|
| Occult Blood | 1 | 2021 | 27 | 0.170 |
Why?
|
| Delayed Diagnosis | 1 | 2021 | 40 | 0.170 |
Why?
|
| Deoxyribonuclease (Pyrimidine Dimer) | 1 | 2021 | 1 | 0.170 |
Why?
|
| Prevalence | 1 | 2025 | 1321 | 0.170 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2022 | 163 | 0.170 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 449 | 0.170 |
Why?
|
| Life Style | 2 | 2023 | 183 | 0.170 |
Why?
|
| Gene-Environment Interaction | 2 | 2012 | 120 | 0.160 |
Why?
|
| Microbiota | 2 | 2017 | 425 | 0.160 |
Why?
|
| Child | 6 | 2024 | 7355 | 0.160 |
Why?
|
| Geography | 1 | 2021 | 240 | 0.160 |
Why?
|
| Meningioma | 1 | 2021 | 62 | 0.160 |
Why?
|
| Immunity, Innate | 2 | 2014 | 463 | 0.160 |
Why?
|
| Meningeal Neoplasms | 1 | 2021 | 69 | 0.160 |
Why?
|
| Transcriptional Activation | 1 | 2021 | 290 | 0.160 |
Why?
|
| Chemoprevention | 2 | 2018 | 93 | 0.160 |
Why?
|
| Health Behavior | 1 | 2021 | 182 | 0.150 |
Why?
|
| Stem Cells | 1 | 2022 | 387 | 0.150 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1546 | 0.150 |
Why?
|
| Treatment Outcome | 6 | 2018 | 9099 | 0.150 |
Why?
|
| Antigens | 2 | 2019 | 224 | 0.150 |
Why?
|
| Lobbying | 1 | 2019 | 3 | 0.150 |
Why?
|
| Intestinal Absorption | 1 | 2019 | 125 | 0.150 |
Why?
|
| Federal Government | 1 | 2019 | 28 | 0.150 |
Why?
|
| Food | 1 | 2019 | 92 | 0.150 |
Why?
|
| Duodenum | 1 | 2019 | 110 | 0.150 |
Why?
|
| Th1 Cells | 2 | 2017 | 167 | 0.150 |
Why?
|
| Endoscopy | 1 | 2022 | 366 | 0.150 |
Why?
|
| Health Surveys | 1 | 2019 | 241 | 0.140 |
Why?
|
| Up-Regulation | 3 | 2020 | 730 | 0.140 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2018 | 40 | 0.140 |
Why?
|
| Capsule Endoscopy | 1 | 2019 | 32 | 0.140 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2018 | 42 | 0.140 |
Why?
|
| Apoptosis | 1 | 2025 | 1721 | 0.140 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2018 | 72 | 0.140 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2018 | 35 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2585 | 0.140 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 36 | 0.140 |
Why?
|
| Microsatellite Repeats | 1 | 2018 | 150 | 0.140 |
Why?
|
| Whipple Disease | 1 | 2018 | 1 | 0.140 |
Why?
|
| Tropheryma | 1 | 2018 | 1 | 0.140 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2018 | 64 | 0.140 |
Why?
|
| Ileum | 1 | 2019 | 167 | 0.140 |
Why?
|
| Aberrant Crypt Foci | 1 | 2018 | 7 | 0.140 |
Why?
|
| Cytoprotection | 1 | 2018 | 51 | 0.140 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 1775 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2019 | 111 | 0.140 |
Why?
|
| Laxatives | 1 | 2018 | 13 | 0.140 |
Why?
|
| Colitis | 1 | 2020 | 261 | 0.130 |
Why?
|
| Anticarcinogenic Agents | 1 | 2018 | 71 | 0.130 |
Why?
|
| Digestive System Neoplasms | 1 | 2017 | 20 | 0.130 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 391 | 0.130 |
Why?
|
| Interferon Type I | 2 | 2017 | 164 | 0.130 |
Why?
|
| Reoviridae Infections | 1 | 2017 | 7 | 0.130 |
Why?
|
| Transcription Factors | 2 | 2023 | 1691 | 0.130 |
Why?
|
| Avena | 1 | 2017 | 18 | 0.130 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2018 | 216 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 2 | 2018 | 962 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 245 | 0.130 |
Why?
|
| Research Support as Topic | 1 | 2017 | 89 | 0.130 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2017 | 83 | 0.130 |
Why?
|
| Organ Culture Techniques | 1 | 2017 | 121 | 0.130 |
Why?
|
| Pharmaceutical Research | 1 | 2016 | 3 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2017 | 119 | 0.120 |
Why?
|
| Drug Evaluation | 1 | 2016 | 109 | 0.120 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2017 | 135 | 0.120 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 149 | 0.120 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 147 | 0.120 |
Why?
|
| Drug Approval | 1 | 2016 | 68 | 0.120 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 373 | 0.120 |
Why?
|
| Genotype | 4 | 2017 | 1866 | 0.120 |
Why?
|
| Leukotrienes | 1 | 2015 | 20 | 0.120 |
Why?
|
| Binding Sites | 1 | 2018 | 1133 | 0.110 |
Why?
|
| Dietary Supplements | 1 | 2016 | 131 | 0.110 |
Why?
|
| Communication | 1 | 2019 | 434 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 486 | 0.110 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2015 | 35 | 0.110 |
Why?
|
| Overweight | 1 | 2016 | 120 | 0.110 |
Why?
|
| Gastrointestinal Agents | 1 | 2017 | 181 | 0.110 |
Why?
|
| Mice | 6 | 2022 | 12269 | 0.110 |
Why?
|
| DNA Repair Enzymes | 1 | 2015 | 61 | 0.110 |
Why?
|
| Isotretinoin | 1 | 2014 | 20 | 0.110 |
Why?
|
| Prognosis | 2 | 2020 | 3911 | 0.110 |
Why?
|
| Cells, Cultured | 3 | 2015 | 2850 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 353 | 0.110 |
Why?
|
| Adenosine Triphosphatases | 1 | 2015 | 141 | 0.110 |
Why?
|
| Phytohemagglutinins | 1 | 2014 | 19 | 0.110 |
Why?
|
| Cysteine | 1 | 2015 | 145 | 0.110 |
Why?
|
| Smad7 Protein | 1 | 2014 | 8 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2017 | 3054 | 0.100 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2014 | 10 | 0.100 |
Why?
|
| CD3 Complex | 1 | 2014 | 135 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 481 | 0.100 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 88 | 0.100 |
Why?
|
| Organ Specificity | 1 | 2015 | 279 | 0.100 |
Why?
|
| Cell Communication | 1 | 2015 | 216 | 0.100 |
Why?
|
| CD28 Antigens | 1 | 2014 | 94 | 0.100 |
Why?
|
| Cell Line | 1 | 2018 | 2464 | 0.100 |
Why?
|
| Dermatologic Agents | 1 | 2014 | 77 | 0.100 |
Why?
|
| Drug Resistance | 1 | 2014 | 233 | 0.100 |
Why?
|
| Electron Transport | 1 | 2013 | 72 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2017 | 621 | 0.100 |
Why?
|
| Kidney Diseases | 1 | 1996 | 315 | 0.100 |
Why?
|
| Nuclear Proteins | 2 | 2015 | 740 | 0.100 |
Why?
|
| Stress, Physiological | 1 | 2015 | 246 | 0.100 |
Why?
|
| Drug Synergism | 1 | 2013 | 315 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2014 | 276 | 0.100 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 484 | 0.100 |
Why?
|
| Lipopolysaccharides | 1 | 2014 | 301 | 0.100 |
Why?
|
| Pathology, Clinical | 2 | 2024 | 38 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2017 | 438 | 0.090 |
Why?
|
| Urban Population | 1 | 2014 | 234 | 0.090 |
Why?
|
| Linkage Disequilibrium | 1 | 2014 | 478 | 0.090 |
Why?
|
| Calcium | 1 | 2016 | 1176 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2011 | 711 | 0.090 |
Why?
|
| Sex Distribution | 2 | 2017 | 174 | 0.090 |
Why?
|
| Genes, myc | 1 | 2012 | 37 | 0.090 |
Why?
|
| Dexamethasone | 1 | 2013 | 312 | 0.090 |
Why?
|
| Spain | 1 | 2011 | 33 | 0.090 |
Why?
|
| North Carolina | 1 | 2011 | 56 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2015 | 663 | 0.090 |
Why?
|
| Animals | 7 | 2022 | 28155 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 394 | 0.090 |
Why?
|
| Kidney | 1 | 1996 | 1111 | 0.080 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 317 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1518 | 0.080 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 156 | 0.080 |
Why?
|
| Introns | 1 | 2011 | 300 | 0.080 |
Why?
|
| Tretinoin | 1 | 2011 | 129 | 0.080 |
Why?
|
| Confidence Intervals | 1 | 2010 | 217 | 0.080 |
Why?
|
| Adjuvants, Immunologic | 1 | 2011 | 173 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 754 | 0.080 |
Why?
|
| Europe | 1 | 2010 | 337 | 0.080 |
Why?
|
| Obesity | 1 | 2016 | 1018 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2015 | 3502 | 0.070 |
Why?
|
| Carcinoma | 1 | 2012 | 439 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2014 | 2026 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2007 | 80 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2007 | 295 | 0.060 |
Why?
|
| Leukemia, Myeloid | 1 | 2007 | 240 | 0.060 |
Why?
|
| Hepatitis B, Chronic | 1 | 2006 | 34 | 0.060 |
Why?
|
| Survival Rate | 1 | 2010 | 1948 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2025 | 1922 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2020 | 1338 | 0.060 |
Why?
|
| Acute Disease | 1 | 2007 | 841 | 0.060 |
Why?
|
| Family Health | 1 | 2006 | 153 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2020 | 524 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 2715 | 0.060 |
Why?
|
| Proof of Concept Study | 1 | 2025 | 56 | 0.060 |
Why?
|
| Gastrectomy | 1 | 2025 | 71 | 0.050 |
Why?
|
| Penetrance | 1 | 2024 | 48 | 0.050 |
Why?
|
| Loss of Function Mutation | 1 | 2024 | 49 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2024 | 82 | 0.050 |
Why?
|
| Intestinal Neoplasms | 1 | 2024 | 68 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2006 | 364 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2019 | 696 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2018 | 666 | 0.050 |
Why?
|
| Disease Management | 1 | 2025 | 358 | 0.050 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2022 | 54 | 0.050 |
Why?
|
| Americas | 1 | 2022 | 19 | 0.050 |
Why?
|
| Cathartics | 1 | 2022 | 27 | 0.040 |
Why?
|
| Machine Learning | 1 | 2025 | 341 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2022 | 113 | 0.040 |
Why?
|
| Immune Tolerance | 2 | 2017 | 375 | 0.040 |
Why?
|
| Esophageal Neoplasms | 1 | 2024 | 344 | 0.040 |
Why?
|
| Pancreas | 1 | 2023 | 258 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2014 | 657 | 0.040 |
Why?
|
| Karyopherins | 1 | 2020 | 15 | 0.040 |
Why?
|
| Morphogenesis | 1 | 2022 | 206 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2024 | 404 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2017 | 1587 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2021 | 225 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2021 | 154 | 0.040 |
Why?
|
| Cell Survival | 1 | 2022 | 1004 | 0.040 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2019 | 18 | 0.040 |
Why?
|
| Butyrophilins | 1 | 2019 | 28 | 0.040 |
Why?
|
| GATA6 Transcription Factor | 1 | 2018 | 13 | 0.040 |
Why?
|
| SOX9 Transcription Factor | 1 | 2018 | 28 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 3830 | 0.040 |
Why?
|
| Mixed Function Oxygenases | 1 | 2018 | 68 | 0.040 |
Why?
|
| Placebo Effect | 1 | 2018 | 35 | 0.030 |
Why?
|
| Bacteriological Techniques | 1 | 2018 | 38 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2018 | 103 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 192 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2022 | 485 | 0.030 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 7 | 0.030 |
Why?
|
| Reoviridae | 1 | 2017 | 6 | 0.030 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2017 | 18 | 0.030 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2017 | 22 | 0.030 |
Why?
|
| Rectum | 1 | 2018 | 149 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2017 | 3435 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 129 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2017 | 55 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 110 | 0.030 |
Why?
|
| Pedigree | 1 | 2018 | 961 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2017 | 100 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2011 | 3829 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 235 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2017 | 321 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 424 | 0.030 |
Why?
|
| Colectomy | 1 | 2017 | 192 | 0.030 |
Why?
|
| Mastectomy | 1 | 2018 | 262 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2017 | 168 | 0.030 |
Why?
|
| Hematuria | 1 | 1996 | 49 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 894 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 893 | 0.030 |
Why?
|
| Receptors, Leukotriene | 1 | 2015 | 10 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2016 | 125 | 0.030 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2015 | 21 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 960 | 0.030 |
Why?
|
| Consensus | 1 | 2017 | 368 | 0.030 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2015 | 32 | 0.030 |
Why?
|
| Transglutaminases | 1 | 2015 | 41 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 110 | 0.030 |
Why?
|
| Autophagy-Related Proteins | 1 | 2015 | 23 | 0.030 |
Why?
|
| Sweden | 1 | 2014 | 45 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 2015 | 147 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2015 | 125 | 0.030 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2015 | 117 | 0.030 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2014 | 7 | 0.030 |
Why?
|
| Cytochrome P450 Family 2 | 1 | 2014 | 4 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2015 | 178 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1729 | 0.030 |
Why?
|
| Intestines | 1 | 2017 | 432 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 206 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2015 | 277 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 1799 | 0.030 |
Why?
|
| ras Proteins | 1 | 2014 | 132 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 657 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 162 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 920 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 178 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2016 | 811 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 836 | 0.020 |
Why?
|
| DNA Glycosylases | 1 | 2012 | 21 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2016 | 896 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 648 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 3476 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2015 | 1524 | 0.020 |
Why?
|
| Dextran Sulfate | 1 | 2011 | 70 | 0.020 |
Why?
|
| G1 Phase | 1 | 2011 | 64 | 0.020 |
Why?
|
| Azoxymethane | 1 | 2011 | 84 | 0.020 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2011 | 9 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2011 | 21 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1243 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2011 | 162 | 0.020 |
Why?
|
| Gliadin | 1 | 2011 | 17 | 0.020 |
Why?
|
| Cetuximab | 1 | 2011 | 118 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2011 | 170 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2012 | 517 | 0.020 |
Why?
|
| Interleukin-23 | 1 | 2011 | 60 | 0.020 |
Why?
|
| Hypertension | 1 | 2016 | 757 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2011 | 108 | 0.020 |
Why?
|
| Seasons | 1 | 2011 | 240 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 1028 | 0.020 |
Why?
|
| Transfection | 1 | 2012 | 880 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 174 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2495 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 263 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 1996 | 870 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 767 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2012 | 295 | 0.020 |
Why?
|
| Registries | 1 | 2014 | 990 | 0.020 |
Why?
|
| Infant | 1 | 1996 | 3220 | 0.020 |
Why?
|
| ROC Curve | 1 | 2011 | 775 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 2755 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 1133 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2011 | 337 | 0.020 |
Why?
|
| Research Design | 1 | 2011 | 617 | 0.020 |
Why?
|
| Surgical Equipment | 1 | 1967 | 3 | 0.020 |
Why?
|
| Peritoneal Dialysis | 1 | 1967 | 31 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2011 | 536 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 1001 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 1395 | 0.010 |
Why?
|
| Rats | 1 | 2011 | 4072 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 1103 | 0.010 |
Why?
|
| Fluorocarbon Polymers | 1 | 1967 | 3 | 0.000 |
Why?
|
| Catheterization | 1 | 1967 | 218 | 0.000 |
Why?
|